The American Journal of Managed Care1d
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...
El Mundo on MSN9h
New advance against HIV: a single annual injection against the infection
Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...
The American Journal of Managed Care4d
CROI to Present New Insights on Long COVID Risk, HIV Cure
One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential ...
Tecovirimat is safe but ineffective as treatment for clade II mpox
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
The Pharma Letter4h
ViiV boosted by Phase IIa data for VH184 and VH499
ViiV Healthcare has announced promising results from two Phase IIa studies of investigational antiretroviral therapies, VH184 ...
BioSpace5h
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
Gilead Presents New HIV Treatment And Cure Research Data
Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). ALLIANCE is an ongoing ...
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
Unsurprisingly, obese individuals (BMI 30-34.9 kg/m 2) had the highest prevalence of EVAF (88%) in the study, followed by class II obese PWH (BMI 35-40 kg/m 2; 69%). However, EVAF was still present in ...
Healio1d
Two more people potentially cured of HIV
Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...
MedPage Today2h
Universal Syphilis Screening in the ED Catches More Cases
Out of more than 37,000 people screened during the first 2 years after implementing universal screening in 2019, the ED ...
ACTG Presents Data from Mpox Study STOMP at CROI
The results from STOMP reinforce the value of randomized clinical trials during outbreaks of infectious diseases, like mpox,” said Past ACTG Chair Judith Currier M.D., M.Sc. “There was considerable ...